Biogen Idec Inc (NASDAQ:BIIB): Institutional Investor Sentiment Down to 0.7

Biogen Inc. (NASDAQ:BIIB) Logo

Sentiment for Biogen Idec Inc (NASDAQ:BIIB)

Biogen Idec Inc (NASDAQ:BIIB) institutional sentiment decreased to 0.7 in 2019 Q2. Its down -0.18, from 0.88 in 2019Q1. The ratio has worsened, as 280 investment managers increased or started new stock positions, while 398 sold and trimmed positions in Biogen Idec Inc. The investment managers in our partner’s database reported: 153.48 million shares, down from 163.29 million shares in 2019Q1. Also, the number of investment managers holding Biogen Idec Inc in their top 10 stock positions decreased from 14 to 10 for a decrease of 4. Sold All: 82 Reduced: 316 Increased: 202 New Position: 78.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $43.65 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 8.82 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

The stock increased 1.86% or $4.32 during the last trading session, reaching $236.63. About 1.45 million shares traded or 1.04% up from the average. Biogen Inc. (NASDAQ:BIIB) has declined 28.25% since September 13, 2018 and is downtrending. It has underperformed by 28.25% the S&P500.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on October, 22. They expect $8.24 EPS, up 11.35 % or $0.84 from last year’s $7.4 per share. BIIB’s profit will be $1.52B for 7.18 P/E if the $8.24 EPS becomes a reality. After $9.15 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -9.95 % negative EPS growth.

Sarissa Capital Management Lp holds 18.75% of its portfolio in Biogen Inc. for 643,000 shares. Krensavage Asset Management Llc owns 176,556 shares or 13.4% of their US portfolio. Moreover, Sector Gamma As has 4.33% invested in the company for 115,126 shares. The California-based Saratoga Research & Investment Management has invested 3.53% in the stock. Waverton Investment Management Ltd, a United Kingdom-based fund reported 253,331 shares.

Since January 1, 0001, it had 1 insider purchase, and 0 selling transactions for $27.21 million activity.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Ratings analysis reveals 32% of Biogen Inc’s analysts are positive. Out of 19 Wall Street analysts rating Biogen Inc, 6 give it “Buy”, 1 “Sell” rating, while 12 recommend “Hold”. The lowest target is $19800 while the high is $416. The stock’s average target of $270.84 is 14.46% above today’s ($236.63) share price. BIIB was included in 31 notes of analysts from March 20, 2019. The firm has “Hold” rating given on Wednesday, July 24 by Canaccord Genuity. Oppenheimer maintained the stock with “Buy” rating in Thursday, March 21 report. The firm earned “Hold” rating on Thursday, March 21 by Barclays Capital. The firm has “Hold” rating given on Thursday, March 21 by Canaccord Genuity. The company was maintained on Thursday, March 21 by Cowen & Co. The rating was maintained by Guggenheim on Thursday, March 21 with “Hold”. The company was maintained on Wednesday, March 20 by Mizuho. BMO Capital Markets maintained it with “Hold” rating and $250 target in Friday, March 22 report. The company was maintained on Thursday, March 21 by Piper Jaffray. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Hold” rating by Goldman Sachs on Thursday, March 21.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Seekingalpha.com which released: “Biogen and Eisai bail on Alzheimer’s candidate elenbecestat – Seeking Alpha” on September 13, 2019, also Nasdaq.com with their article: “Ionis Pharmaceuticals Looks to Partners to Pay the Bills – Nasdaq” published on August 14, 2019, Forbes.com published: “Which Stock: Tesla or Biogen? 2 Worlds. Same Price – Forbes” on August 22, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Noteworthy Friday Option Activity: CI, ITW, BIIB – Nasdaq” published on August 30, 2019 as well as Nasdaq.com‘s news article titled: “Better Buy: Gilead Sciences vs. Biogen – Nasdaq” with publication date: September 01, 2019.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.